On Monday, Shares of Axalta Coating Systems Ltd (NYSE:AXTA), lost -2.25% to $27.80.
Axalta Coating Systems, will showcase its Harmonized Coating Technologies™, a merged coating system, in China at the SURCAR 2015 automotive body finishing show in Shanghai.
Combining latest generation waterborne coatings with established high solid coatings, Axalta’s Harmonized Coating Technologies aim to meet the emerging needs of light vehicle original equipment manufacturers (OEMs) to achieve more sustainable and efficient car manufacturing.
Axalta Coating Systems Ltd., through its auxiliaries, manufactures, markets, and distributes high performance coatings products primarily for the transportation industry. It operates through two segments, Performance Coatings and Transportation Coatings.
Shares of Finish Line Inc (NASDAQ:FINL), inclined 0.77% to $24.71, during its last trading session.
Athletic retailer The Finish Line, Inc. (FINL) has teamed up with PUMA® for the launch of its latest customer experience enhancement – the PUMA edge at Finish Line. Finish Line will open ten initial PUMA experiences within targeted retail locations across the country and online at FinishLine.com in August. The experience comprises expanded product offerings with a unique approach to marketing and content creation designed specifically to connect the PUMA brand to the Finish Line consumer.
The shop launches will be supported by several digital and social media initiatives counting digital paid media, email marketing with a mobile focus, geo-targeted Facebook and Twitter posts in addition to blog and website placements.
The Finish Line, Inc., together with its auxiliaries, operates as a specialty retailer of athletic shoes, apparel, and accessories in the United States. It operates Finish Line stores that offer athletic shoes, in addition to apparel and accessories for men, women, and kids. The company also operates Running Specialty stores offering men’s and women’s performance running shoes, in addition to an assortment of performance apparel and accessories.
At the end of Monday’s trade, Shares of Sangamo Biosciences, Inc. (NASDAQ:SGMO), lost -3.95% to $7.06.
Sangamo BioSciences, presented data demonstrating sustained functional control of viral load in the absence of antiretroviral drugs (ART) in two of three HIV-infected subjects treated in Cohort 3 of its Phase 1/2 study (SB-728-1101) of its ZFP Therapeutic (SB-728-T) for the treatment of HIV/AIDS. The subjects remain on extended treatment interruption (TI), past the initial 16 week TI period. The data, which led to expanded enrollment of this Cohort, were presented at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego from September 17-21.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables precise and highly specific genome modification and gene regulation.
Finally, PTC Therapeutics, Inc. (NASDAQ:PTCT), ended its last trade with -7.53% gain, and closed at $35.23.
PTC Therapeutics International, declared that Health Canada has initiated their review of the company’s New Drug Submission (NDS) for Translarna (ataluren) to treat nonsense mutation dystrophinopathy. The NDS will be reviewed with advance consideration under the Health Canada policy of Notice of Compliance with Conditions (NOC/c).
If approved, Translarna would be the first treatment available to patients in Canada that addresses an underlying cause of dystrophinopathy, counting nonsense mutation Duchenne muscular dystrophy (nmDMD).
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
